Sangamo Therapeutics, Inc. (SGMOQ)
0.117
+0.01
(+6.36%)
USD |
OTCM |
Nov 13, 16:00
Sangamo Therapeutics Enterprise Value : 40.22M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 40.22M |
| November 12, 2026 | 37.32M |
| November 11, 2026 | 35.66M |
| November 10, 2026 | 37.32M |
| November 09, 2026 | 37.32M |
| November 06, 2026 | 38.97M |
| November 05, 2026 | 38.97M |
| November 04, 2026 | 39.39M |
| November 03, 2026 | 40.22M |
| November 02, 2026 | 39.39M |
| October 30, 2026 | 39.80M |
| October 29, 2026 | 41.42M |
| October 28, 2026 | 40.63M |
| October 27, 2026 | 40.67M |
| October 26, 2026 | 39.84M |
| October 23, 2026 | 39.39M |
| October 22, 2026 | 39.39M |
| October 21, 2026 | 35.24M |
| October 20, 2026 | 37.32M |
| October 19, 2026 | 33.67M |
| October 16, 2026 | 37.40M |
| October 15, 2026 | 50.12M |
| October 14, 2026 | 49.70M |
| October 13, 2026 | 49.79M |
| October 12, 2026 | 53.89M |
| Date | Value |
|---|---|
| October 09, 2026 | 52.97M |
| October 08, 2026 | 49.79M |
| October 07, 2026 | 49.74M |
| October 06, 2026 | 49.74M |
| October 05, 2026 | 51.48M |
| October 02, 2026 | 52.85M |
| October 01, 2026 | 51.94M |
| September 30, 2026 | 52.64M |
| September 29, 2026 | 49.74M |
| September 28, 2026 | 51.03M |
| September 25, 2026 | 51.40M |
| September 24, 2026 | 52.69M |
| September 23, 2026 | 53.31M |
| September 22, 2026 | 52.19M |
| September 21, 2026 | 50.28M |
| September 18, 2026 | 51.77M |
| September 17, 2026 | 50.20M |
| September 16, 2026 | 52.89M |
| September 15, 2026 | 52.77M |
| September 14, 2026 | 52.85M |
| September 11, 2026 | 53.27M |
| September 10, 2026 | 56.12M |
| September 09, 2026 | 55.96M |
| September 08, 2026 | 58.40M |
| September 04, 2026 | 58.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Oncolytics Biotech, Inc. | 42.45M |
| Sarepta Therapeutics, Inc. | 1.897B |
| Anixa Biosciences, Inc. | 75.65M |
| Vicapsys Life Sciences, Inc. | 16.68M |
| Protagenic Therapeutics, Inc. | 0.7558M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.00M |
| Revenue (Quarterly) | 1.442M |
| Total Expenses (Quarterly) | 32.44M |
| EPS Diluted (Quarterly) | -0.0796 |
| Gross Profit Margin (Quarterly) | 39.18% |
| Profit Margin (Quarterly) | -2.15K% |
| Earnings Yield | -327.4% |
| Normalized Earnings Yield | -304.96 |